These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis. Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894 [TBL] [Abstract][Full Text] [Related]
4. Categorization of COPD patients in Turkey via GOLD 2013 strategy document: ALPHABET study. Gunen H; Yilmaz M; Aktas O; Ergun P; Ortakoylu MG; Demir A; Cetinkaya P; Gurgun A; Otlu M; Cilli A; Yilmaz U; Kokturk N; Candemir I; Yakar HI; Ar I; Konya A Int J Chron Obstruct Pulmon Dis; 2015; 10():2485-94. PubMed ID: 26622176 [TBL] [Abstract][Full Text] [Related]
5. Adherence to a COPD treatment guideline among patients in Hong Kong. Chan KP; Ko FW; Chan HS; Wong ML; Mok TY; Choo KL; Hui DS Int J Chron Obstruct Pulmon Dis; 2017; 12():3371-3379. PubMed ID: 29238182 [TBL] [Abstract][Full Text] [Related]
6. A cross-sectional survey of current treatment and symptom burden of patients with COPD consulting for routine care according to GOLD 2014 classifications. Ding B; Small M; Holmgren U Int J Chron Obstruct Pulmon Dis; 2017; 12():1527-1537. PubMed ID: 28579771 [TBL] [Abstract][Full Text] [Related]
7. Initiation of triple therapy maintenance treatment among patients with COPD in the US. Simeone JC; Luthra R; Kaila S; Pan X; Bhagnani TD; Liu J; Wilcox TK Int J Chron Obstruct Pulmon Dis; 2017; 12():73-83. PubMed ID: 28053518 [TBL] [Abstract][Full Text] [Related]
8. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Price D; West D; Brusselle G; Gruffydd-Jones K; Jones R; Miravitlles M; Rossi A; Hutton C; Ashton VL; Stewart R; Bichel K Int J Chron Obstruct Pulmon Dis; 2014; 9():889-904. PubMed ID: 25210450 [TBL] [Abstract][Full Text] [Related]
9. Adherence to GOLD guideline treatment recommendations among pulmonologists in Turkey. Sen E; Guclu SZ; Kibar I; Ocal U; Yilmaz V; Celik O; Cimen F; Topcu F; Orhun M; Tereci H; Konya A; Ar I; Saryal S Int J Chron Obstruct Pulmon Dis; 2015; 10():2657-63. PubMed ID: 26715844 [TBL] [Abstract][Full Text] [Related]
10. The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK. Edwards SC; Fairbrother SE; Scowcroft A; Chiu G; Ternouth A; Lipworth BJ Int J Chron Obstruct Pulmon Dis; 2016; 11():2851-2858. PubMed ID: 27920512 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological approach and adherence to treatment recommendations in frequently and non-frequently exacerbating COPD patients from Italy: MISTRAL - The prospective cohort, observational study. Scalone G; Nava S; Ventrella F; Bussoli G; Catapano GA; Pennisi A; Dadduzio F; Schino P; Pela R; Bartezaghi M; Morini P; Porpiglia PA; Muscianisi E; Pulm Pharmacol Ther; 2018 Dec; 53():68-77. PubMed ID: 30193866 [TBL] [Abstract][Full Text] [Related]
12. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study. Casas A; Montes de Oca M; Menezes AM; Wehrmeister FC; Lopez Varela MV; Mendoza L; Ramírez L; Miravitlles M Int J Chron Obstruct Pulmon Dis; 2018; 13():1545-1556. PubMed ID: 29785104 [TBL] [Abstract][Full Text] [Related]
13. An evaluation of early medication use for COPD: a population-based cohort study. Falk J; Dik N; Bugden S Int J Chron Obstruct Pulmon Dis; 2016; 11():3101-3108. PubMed ID: 27994449 [TBL] [Abstract][Full Text] [Related]
14. The reasons for triple therapy in stable COPD patients in Japanese clinical practice. Miyazaki M; Nakamura H; Takahashi S; Chubachi S; Sasaki M; Haraguchi M; Terai H; Ishii M; Fukunaga K; Tasaka S; Soejima K; Asano K; Betsuyaku T; Int J Chron Obstruct Pulmon Dis; 2015; 10():1053-9. PubMed ID: 26082629 [TBL] [Abstract][Full Text] [Related]
15. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy. Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905 [TBL] [Abstract][Full Text] [Related]
16. Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey. Ding B; Small M Int J Chron Obstruct Pulmon Dis; 2017; 12():1753-1763. PubMed ID: 28670116 [TBL] [Abstract][Full Text] [Related]
17. COPD patients' characteristics, usual care, and adherence to guidelines: the Greek UNLOCK study. Tsiligianni I; Kampouraki M; Ierodiakonou D; Poulonirakis I; Papadokostakis P Int J Chron Obstruct Pulmon Dis; 2019; 14():547-556. PubMed ID: 30880944 [TBL] [Abstract][Full Text] [Related]
18. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D; Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625 [TBL] [Abstract][Full Text] [Related]
19. Exacerbation recovery patterns in newly diagnosed or maintenance treatment-naïve patients with COPD: secondary analyses of TICARI 1 trial data. Mannino DM; Clerisme-Beaty EM; Franceschina J; Ting N; Leidy NK Int J Chron Obstruct Pulmon Dis; 2018; 13():1515-1525. PubMed ID: 29785101 [TBL] [Abstract][Full Text] [Related]
20. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design. Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]